Review: side effects of approved molecular targeted therapies in solid cancers.

Keywords

Humanities, Political science, Philosophy

References

• Trastuzumab and breast cancer.Thomas M. Behr, Martin Béhé, B Wörmann — 2001
• Kinase Inhibition with BAY 43–9006 in Renal Cell CarcinomaMurray S. Shereshewsky — 2004
• Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.Seiichi Yano, Kaoru Kondo, Motonori Yamaguchi — 2003
• Reversible posterior leukoencephalopathy syndrome and bevacizumab.Cevher Ozcan, Stuart J. Wong, Parameswaran Hari — 2006
• Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome.F Mujić, Mark Lloyd, M J Cuadrado — 1995
• The EGF receptor - an essential regulator of multiple epidermal functions.M Jost, Csaba Kari, Ulrich Rodeck — 2000
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.José Baselga, David G. Pfister, Michael R. Cooper — 2000
• Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart.Iván P. Uray, John H. Connelly, Vilmos Thomázy — 2002
• Angiogenesis inhibitors: from laboratory to clinical application.Toshikazu Nakamura, Kunio Matsumoto — 2005
• Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsWenle Xia, Catherine Gérard, Lei-Hua Liu — 2005
• Cloning and Biological Activity of Epigen, a Novel Member of the Epidermal Growth Factor Superfamily*Lorna Strachan, J. Greg Murison, Ross L. Prestidge — 2001
• Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysWenle Xia, Robert J. Mullin, Barry R. Keith — 2002
• Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathyC. Özcelik, Bettina Erdmann, Bernhard Pilz — 2002
• Vascular endothelial growth factor is a secreted angiogenic mitogen.David W. M. Leung, George Cachianes, Wun-Jing Kuang — 1989
• Role of Raf in Vascular Protection from Distinct Apoptotic StimuliAlireza Alavi, John Hood, Ricardo F. Frausto — 2003
• Tyrosine kinase inhibition and grey hair.Caroline Robert, Alan Spatz, Sandrine Faivre — 2003
• SCF/c‐kit signaling is required for cyclic regeneration of the hair pigmentation unitNatalia V. Botchkareva, Mary K. Khlgatian, B. Jack Longley — 2001
• Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.Anna Liza C. Agero, Stephen W. Dusza, Cristiane Benvenuto-Andrade — 2006
• Structural evidence that endothelial cell growth factor beta is the precursor of both endothelial cell growth factor alpha and acidic fibroblast growth factor.Wilson H. Burgess, Tevie Mehlman, D R Marshak — 1986
• Sorafenib in advanced clear-cell renal-cell carcinoma.Bernard Escudier, Tim Eisen, Walter M. Stadler — 2007

Cited by

• Organtoxizität medikamentöser TumortherapienLuis González Vaqué — 2013
• Development of Folate-Thioglycolate-Gold Nanoconjugates by Using Citric Acid-PEG Branched Polymer for Inhibition of MCF-7 Cancer Cell Proliferation.Robert E. Brown — 2018
• Old disease, new targets. Part-II, haematological malignancies.Shiyam Kumar, Nehal Masood, Salman Naseem Adil — 2009
• Intrinsic and Acquired Drug Resistance in Malignant TumorsT. H. Lippert, H. -J. Ruoff, M Volm — 2008
• Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology.Em Dietrich, K. Antoniades — 2012
• Discovery of molecular mechanisms of lignan justicidin A using L1000 gene expression profiles and the Library of Integrated Network-based Cellular Signatures databaseShen‐Jeu Won, Hsing-Chih Wu, Kuan‐Ting Lin — 2015
• Mécanismes moléculaires de l'acquisition d'une sensibilité à l'apoptose induite par l'ABT-737 et d'une résistance à l'anoïkis de cellules coliques métastatiquesA. Azzabi — 2013
• A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer | PERKelly Khai Li Yap, Debu Tripathy — 2015
• Anchor-based classification and type-C inhibitors for tyrosine kinasesKai‐Cheng Hsu, Tzu-Ying Sung, Chih-Ta Lin — 2015
• Chaperone-assisted protein aggregate reactivation: Different solutions for the same problem.Alejandra Aguado, José Ángel Fernández-Higuero, Fernando Moro — 2015
• Analysis of the adverse reactions induced by natural product‐derived drugsZhi‐Ping Zeng, Jian‐Guo Jiang — 2010
• Gestion des principaux effets indésirables des thérapies ciblées par voie orale : quel type d'outil pour le pharmacien d'officine ?Nathalie Ziener — 2012
• Biotherapeutics for human eosinophil associated disordersAnubha Singh, Deepak Kumar Singh, Usha Bhoria — 2015
• Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.Maria E. Arcila, Christopher Lau, Khédoudja Nafa — 2011
• Molecular genetic aspects and characterization of the extracellular matrix of myxoid tumours of soft tissueStefan M. Willems — 2011
• Natural human immunoglobulins in cancer immunotherapy.H. Peter Vollmers, Stephanie Brändlein — 2009
• GENOMIC AND TRANSCRIPTOME PROFILING OF EPITHELIAL OVARIAN CANCERRebecca JZ Menzies, Yury V. Bukhman, Nancy F. L. Ng — 2008
• [Panitumumab-treatment of metastatic colorectal cancer].Béla Pikó — 2009
• Oral antineoplastic agents: how do we care about adherence?Marie Barillet, Virginie Prévost, Florence Joly — 2015
• Locally Advanced or Metastatic Lung Adenocarcinomas with Egfr Mutantions. Treatment Experience and Advers EventsAlvydas Česas, Aušra Bankauskaitė, Jolanta Česienė — 2014

Related papers

No related papers recorded.